Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Neurology · Hereditary ATTR amyloidosis

What Is the ATTRv V30M Carrier Monitoring Protocol?

At a Glance

Asymptomatic ATTRv V30M carriers should undergo comprehensive neurological, cardiac, and blood evaluations every 6 to 12 months, starting 10 years before their predicted age of onset. This protocol detects early signs of the disease (phenoconversion) so treatment can begin promptly.

In this answer

2 sections

01

When to Start Monitoring

02

The Monitoring Checklist

If you have tested positive for the V30M mutation but currently feel fine, you are considered an “asymptomatic carrier.” Because early treatment is critical for hereditary ATTR amyloidosis (ATTRv), experts recommend a structured, proactive monitoring protocol to catch the very first signs of the disease—a transition phase known as phenoconversion [1]. The standard recommendation is to undergo comprehensive neurological, cardiac, and blood evaluations every 6 to 12 months with an amyloidosis specialist or a specialized multidisciplinary care team [2][3].

When to Start Monitoring

Your care team will likely determine when to begin intensive monitoring based on your Predicted Age of Disease Onset (PADO) [4]. This is usually calculated by looking at the exact age your blood relatives first showed symptoms. Routine surveillance typically begins approximately 10 years before your PADO to establish your healthy baseline and detect any subtle changes as early as possible [4][5].

The Monitoring Checklist

Catching phenoconversion requires a multi-system approach, as the V30M mutation primarily affects the nerves and heart [6][7]. General practitioners and standard specialists may not be familiar with these specific guidelines, so you should ensure your care is managed by experts at a dedicated amyloidosis center who can easily order these tests [8]. You may even wish to bring this checklist to your appointments.

Neurological and Autonomic Testing

Since the V30M mutation often impacts the nervous system first, specialized nerve tests are a core part of surveillance:

  • Clinical Neurological Exam: A regular check of your reflexes, muscle strength, and physical sensation [9].
  • Nerve Conduction Studies: Tests that measure how fast electrical signals move through your large nerves [10].
  • Small-Fiber Assessments: The smallest nerve fibers are often damaged first in ATTRv. Your specialist may use Sudoscan (a quick, non-invasive test measuring sweat gland function) or an intraepidermal nerve fiber density (IENFD) test (a small skin biopsy) to detect early damage [11][12][13]. Because these are highly specialized tests, they may only be available at dedicated rare-disease or amyloidosis treatment centers [8].
  • Autonomic Function Testing: Evaluates processes your body controls automatically, like your blood pressure, heart rate, and digestion [14][15].

Blood Biomarkers

  • Serum Neurofilament Light Chain (sNfL): This is a highly recommended, albeit specialized, blood test that measures a specific protein released when nerve cells are damaged [16][17]. By tracking your sNfL levels over time, specialists can spot early nerve damage before you even feel symptoms [1][16].
  • Cardiac Biomarkers (NT-proBNP and Troponin): These specific blood tests measure stress and damage to the heart muscle. Monitoring them regularly helps detect early cardiac involvement before you notice cardiovascular symptoms [18][19].

Cardiac Evaluation

Even if your mutation primarily affects the nerves, your heart must be monitored regularly:

  • EKG (Electrocardiogram) and Echocardiogram: Routine tests typically performed every 6 to 12 months to check your heart’s electrical activity and physical structure [9][20].
  • 99mTc-PYP Scintigraphy (PYP Scan): Because standard EKGs and echocardiograms might appear normal early on, this specialized nuclear imaging test can detect amyloid protein deposits much sooner [21]. Rather than being performed every 6 months, a PYP scan is generally done once to establish a baseline, and then only repeated if your other cardiac tests or blood biomarkers show abnormalities [22][21].

By sticking to this structured schedule, you and your care team can confidently track your health. If any of these tests come back abnormal, your doctor will likely order confirmatory tests to verify phenoconversion before initiating disease-modifying treatments [2][23].

Watch for “red flag” symptoms between your appointments—such as numbness, tingling, dizzy spells when standing, severe constipation, sudden unexplained diarrhea, alternating between the two, or getting full very quickly when eating. Contact your specialist immediately if these occur rather than waiting for your next scheduled visit [24][2].

Common questions in this guide

When should an asymptomatic ATTRv V30M carrier start medical monitoring?
Experts typically recommend starting intensive monitoring about 10 years before your Predicted Age of Disease Onset (PADO). This age is usually based on when your blood relatives first started showing symptoms.
How often do asymptomatic ATTRv carriers need neurological and cardiac testing?
Standard guidelines recommend comprehensive neurological, cardiac, and blood evaluations every 6 to 12 months. This regular routine helps establish a healthy baseline and detects the very earliest signs of the disease.
What blood tests are used to monitor ATTRv carriers?
Doctors use cardiac biomarkers like NT-proBNP and Troponin to check for early heart strain. They also highly recommend measuring serum neurofilament light chain (sNfL), which helps detect early nerve damage before you even feel symptoms.
What are the red flag symptoms of ATTR amyloidosis to watch for?
Watch for early signs like numbness, tingling, dizzy spells when standing, alternating severe constipation and diarrhea, or feeling full very quickly when eating. If you notice these between appointments, contact your specialist immediately.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What do you estimate my Predicted Age of Disease Onset (PADO) to be, and exactly when should my 6- to 12-month monitoring begin?
  2. 2.Are you able to order specialized tests like serum neurofilament light chain (sNfL) and Sudoscan/IENFD, or should I be referred to an amyloidosis Center of Excellence?
  3. 3.Can we establish my baseline for cardiac biomarkers (NT-proBNP and Troponin) and a baseline PYP scan at my next appointment?
  4. 4.If one of my surveillance tests shows a slight abnormality, what are the exact next steps and confirmatory tests before we consider starting disease-modifying therapies?
  5. 5.Who will serve as the primary coordinator for my multi-system care, ensuring my neurology and cardiology results are reviewed together?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

ATTRv V30M Medications: Pills, Shots, or IV Infusions?How Does ATTRv V30M Amyloidosis Affect Eye Health?Talk to Family About ATTRv V30M Genetic TestingHow to Manage Dizziness & GI Issues in ATTRv AmyloidosisHow to Tell ATTRv V30M From CIDP & Diabetic Neuropathy?Are V30M and p.Val50Met the Same Genetic Mutation?Is Liver Transplant Still Used for V30M Amyloidosis?What Is the sNfL Test for ATTRv V30M Amyloidosis?Questions to Ask an ATTRv V30M Amyloidosis SpecialistWho is at Risk for ATTRv V30M Amyloidosis?Why Do PYP Scans Miss Heart Amyloidosis in V30M?Why Do TTR Silencers Require Vitamin A Supplements?

References

References (24)
  1. 1

    Diagnostic & therapeutic challenges of presymptomatic hereditary transthyretin amyloidosis.

    Echaniz-Laguna A, Algalarrondo V

    Revue neurologique 2025; (181(9)):915-921 doi:10.1016/j.neurol.2025.06.016.

    PMID: 41238320
  2. 2

    Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression.

    Adams D, Algalarrondo V, Polydefkis M, et al.

    Orphanet journal of rare diseases 2021; (16(1)):411 doi:10.1186/s13023-021-01960-9.

    PMID: 34602081
  3. 3

    Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal.

    Ando Y, Waddington-Cruz M, Sekijima Y, et al.

    Orphanet journal of rare diseases 2023; (18(1)):323 doi:10.1186/s13023-023-02910-3.

    PMID: 37828588
  4. 4

    Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations.

    Conceição I, Damy T, Romero M, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2019; (26(1)):3-9 doi:10.1080/13506129.2018.1556156.

    PMID: 30793974
  5. 5

    Early cardiac sympathetic denervation in hereditary transthyretin amyloidosis: 123I-metaiodobenzylguanidine findings and correlation with skin biopsy.

    Frantellizzi V, Cambieri C, Galosi E, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2026; 1-13 doi:10.1080/13506129.2026.2636657.

    PMID: 41773910
  6. 6

    Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers.

    Beauvais D, Labeyrie C, Cauquil C, et al.

    Journal of neurology, neurosurgery, and psychiatry 2024; (95(6)):489-499 doi:10.1136/jnnp-2023-332180.

    PMID: 37875336
  7. 7

    Diagnosis and Management of Mixed Phenotype Hereditary Transthyretin Amyloidosis: A Case-Based, Canadian Perspective.

    Fine N, Ducharme A, Matte G, et al.

    CJC open 2025; (7(5)):614-627 doi:10.1016/j.cjco.2025.03.002.

    PMID: 40433205
  8. 8

    Transthyretin Amyloid Cardiomyopathy-2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options.

    Tschöpe C, Elsanhoury A, Kristen AV

    Journal of clinical medicine 2025; (14(13)) doi:10.3390/jcm14134785.

    PMID: 40649158
  9. 9

    Nerve Conduction Studies of Dorsal Sural Nerve: Normative Data and Its Potential Application in ATTRv Pre-Symptomatic Subjects.

    Luigetti M, Guglielmino V, Romozzi M, et al.

    Brain sciences 2022; (12(8)) doi:10.3390/brainsci12081037.

    PMID: 36009100
  10. 10

    Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flags.

    Siemer JM, Grote-Levi L, Hänselmann A, et al.

    Scientific reports 2025; (15(1)):35028 doi:10.1038/s41598-025-21745-5.

    PMID: 41057524
  11. 11

    Sudoscan in ATTRv Amyloidosis: A Potential Marker of Disease Progression?

    Romano A, Guglielmino V, Vitali F, et al.

    Neurology and therapy 2025; (14(3)):787-800 doi:10.1007/s40120-025-00721-1.

    PMID: 40091132
  12. 12

    Skin amyloid deposits and nerve fiber loss as markers of neuropathy onset and progression in hereditary transthyretin amyloidosis.

    Leonardi L, Adam C, Beaudonnet G, et al.

    European journal of neurology 2022; (29(5)):1477-1487 doi:10.1111/ene.15268.

    PMID: 35100482
  13. 13

    Correlation between a commercial electrophysiological test of sudomotor function and intraepidermal nerve fiber density in hereditary transthyretin amyloidosis.

    Masuda T, Misumi Y, Nomura T, et al.

    Muscle & nerve 2024; (69(1)):99-102 doi:10.1002/mus.28005.

    PMID: 37960924
  14. 14

    Cardiovascular autonomic failure in hereditary transthyretin amyloidosis and TTR carriers is an early and progressive disease marker.

    Chiaro G, Stancanelli C, Koay S, et al.

    Clinical autonomic research : official journal of the Clinical Autonomic Research Society 2024; (34(3)):341-352 doi:10.1007/s10286-024-01038-z.

    PMID: 38769233
  15. 15

    Evaluation of autonomic dysfunction in hereditary transthyretin amyloidosis.

    Martínez-Valle F, Casasnovas-Pons C, Romero-Acebal M, Galán-Dávila L

    Neurologia 2025; (40(9)):915-923 doi:10.1016/j.nrleng.2025.08.002.

    PMID: 41198384
  16. 16

    Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.

    Berends M, Brunger AF, Bijzet J, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2024; (31(2)):132-141 doi:10.1080/13506129.2024.2327342.

    PMID: 38477065
  17. 17

    [Is neurofilament light chain useful as a disease progression marker for ATTRv amyloidosis? A literature review].

    Sekijima Y, Ueda M, Takahashi K, Kitaoka H

    Rinsho shinkeigaku = Clinical neurology 2025; (65(4)):251-259 doi:10.5692/clinicalneurol.cn-002063.

    PMID: 40128929
  18. 18

    High-Sensitivity Cardiac Troponin T to Exclude Cardiac Involvement in TTR Variant Carriers and ATTRv Amyloidosis Patients.

    Tingen HSA, Berends M, Tubben A, et al.

    Journal of clinical medicine 2024; (13(3)) doi:10.3390/jcm13030810.

    PMID: 38337504
  19. 19

    Hereditary Transthyretin Cardiac Amyloidosis With the p.V142I Variant: Mechanistic Insights and Diagnostic Challenges.

    Vanhentenrijk S, Grodin JL, Augusto SN, Tang WHW

    Circulation. Heart failure 2025; (18(6)):e012469 doi:10.1161/CIRCHEARTFAILURE.124.012469.

    PMID: 40084403
  20. 20

    Follow-up in transthyretin familial amyloid polyneuropathy: Useful investigations.

    Escolano-Lozano F, Geber C, Barreiros AP, Birklein F

    Journal of the neurological sciences 2020; (413()):116776 doi:10.1016/j.jns.2020.116776.

    PMID: 32203746
  21. 21

    Hereditary transthyretin amyloidosis with hydrocephalus at 27 years old: A case report.

    Kamimoto H, Tomioka D, Hanato K, et al.

    Journal of cardiology cases 2024; (29(5)):201-204 doi:10.1016/j.jccase.2024.01.002.

    PMID: 39100516
  22. 22

    Updates in Cardiac Amyloidosis Diagnosis and Treatment.

    Stern LK, Kittleson MM

    Current oncology reports 2021; (23(4)):47 doi:10.1007/s11912-021-01028-8.

    PMID: 33725199
  23. 23

    Diagnosis and treatment of hereditary transthyretin amyloidosis with polyneuropathy in the United States: Recommendations from a panel of experts.

    Karam C, Mauermann ML, Gonzalez-Duarte A, et al.

    Muscle & nerve 2024; (69(3)):273-287 doi:10.1002/mus.28026.

    PMID: 38174864
  24. 24

    Transthyretin Cardiac Amyloidosis: A Cardio-Orthopedic Disease.

    Perfetto F, Zampieri M, Bandini G, et al.

    Biomedicines 2022; (10(12)) doi:10.3390/biomedicines10123226.

    PMID: 36551982

This page provides educational information on ATTRv V30M monitoring protocols. Always consult your amyloidosis specialist to determine the appropriate testing schedule and care plan for your specific situation.

Get notified when new evidence is published on ATTRV30M amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.